Safety and Immunogenicity Study of MEDI-517 (GSK 580299) With or Without Adjuvant in Healthy Adult Females

NCT00693615 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Infections, Papillomavirus

Interventions

BIOLOGICAL: MEDI-517 HPV-16/18 VLP AS04 vaccine
BIOLOGICAL: MEDI-517 HPV-16/18 VLP vaccine with Al(OH)3
BIOLOGICAL: MEDI-517 HPV-16/18 VLP vaccine without adjuvant

Sponsor

GlaxoSmithKline